Date
12/19/2024 2:15:58 AM
(MENAFN- GlobeNewsWire - Nasdaq) DXS INTERNATIONAL PLC (AQSE: DXSP)
DXS AGM 2024 Statement
The Board of DXS International plc (“the Company” or“DXSP”), the AQSE Growth market quoted healthcare information and digital clinical decision support systems provider, is pleased to publish an update on operations and pipeline progress ahead of its Annual General Meeting (" AGM ") taking place today at Noon at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB.
During the AGM, the Company's CEO, David Immelman, will provide an update on DXS's progress. The Company made good progress in 2024 with both Aios SMART Referrals and ExpertCare, and achieved an NHS price increase.
Aios SMART Referrals
The existing Point of Care solution was replaced with Aios SMART Referrals, a new cloud based solution. NHS Electronic Referral System integration was completed, certified and NHS IMI accredited on the NHS G Cloud 14 Procurement Framework. SMART Referrals are now used for 10% of all referrals in England, an estimated 1.8 million per annum. Currently 22% of newly established Integrated Care Boards (ICBs) have some of their practices using Smart Referrals. These current paid for practices cover approx. 6.5m registered patients and there is the opportunity to convert the remaining GP practices to the Smart Referrals solution covering an additional 6.5m patients and to gain new market share in the remaining 78% of ICBs.
ExpertCare
ExpertCare is a unique Long Term Condition therapeutic management solution. Currently it has completed 75% or Phase 3 of 4 Phases of an Innovate UK grant with Health Innovate East, as announced in November 2023, with good results and York university is conducting an economic impact assessment. The first commercial sale was secured as announced on 29 October 2024.
Summary
The Company is looking to expand into at least one EU or other territory in 2025 and looks forward to updating the market in due course.
A Presentation that the CEO will deliver during the AGM is available for download from the Company's website at
We would like to thank our shareholders and other stakeholders for their continued support.
The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).
Contacts:
David Immelman
DXS International plc
| 01252 719800 |
AQSE Corporate Broker and Corporate Advisor
Hybridan LLP
Claire Louise Noyce |
020 3764 2341 |
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.
MENAFN19122024004107003653ID1109010391
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.